- Home
- ABEO vs EIC Comparison
ABEO vs EIC Comparison
Compare ABEO & EIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABEO
- EIC
- Stock Information
- Founded
- ABEO 1974
- EIC N/A
- Country
- ABEO United States
- EIC United States
- Employees
- ABEO N/A
- EIC N/A
- Industry
- ABEO Biotechnology: Pharmaceutical Preparations
- EIC Finance/Investors Services
- Sector
- ABEO Health Care
- EIC Finance
- Exchange
- ABEO Nasdaq
- EIC Nasdaq
- Market Cap
- ABEO 256.9M
- EIC 349.4M
- IPO Year
- ABEO 1980
- EIC 2019
- Fundamental
- Price
- ABEO $5.69
- EIC $13.78
- Analyst Decision
- ABEO Strong Buy
- EIC Strong Buy
- Analyst Count
- ABEO 6
- EIC 1
- Target Price
- ABEO $18.00
- EIC $17.50
- AVG Volume (30 Days)
- ABEO 1.1M
- EIC 204.2K
- Earning Date
- ABEO 08-11-2025
- EIC 08-05-2025
- Dividend Yield
- ABEO N/A
- EIC 17.48%
- EPS Growth
- ABEO N/A
- EIC N/A
- EPS
- ABEO N/A
- EIC 0.55
- Revenue
- ABEO N/A
- EIC $51,224,692.00
- Revenue This Year
- ABEO N/A
- EIC $42.67
- Revenue Next Year
- ABEO $323.51
- EIC $29.16
- P/E Ratio
- ABEO N/A
- EIC $24.89
- Revenue Growth
- ABEO N/A
- EIC 68.61
- 52 Week Low
- ABEO $3.93
- EIC $12.63
- 52 Week High
- ABEO $7.32
- EIC $16.71
- Technical
- Relative Strength Index (RSI)
- ABEO 47.54
- EIC 59.85
- Support Level
- ABEO $5.68
- EIC $13.64
- Resistance Level
- ABEO $5.93
- EIC $13.92
- Average True Range (ATR)
- ABEO 0.26
- EIC 0.16
- MACD
- ABEO -0.01
- EIC 0.07
- Stochastic Oscillator
- ABEO 56.25
- EIC 96.83
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
About EIC Eagle Point Income Company Inc.
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.